Russian drugmaker Geropharm has announced the timeline for completing its clinical trial of a semaglutide‑based drug for overweight and obese adolescents. The company aims to complete the trial in 2026, chief executive Pyotr Rodionov told the Semashko Russian Pharmaceutical Forum in St Petersburg.
If successful, the drug would be the first in Russia approved for semaglutide use in adolescents, Rodionov said. At the same time, the company is conducting a trial of another obesity drug for adolescents containing tirzepatide. Geropharm received Health Ministry approval for that trial in 2025.
“The studies are ongoing, and we expect to update the prescribing information in 2027,” Rodionov noted.
Rodionov also said that Geropharm plans to invest around 7‑10 billion roubles in building a new pharmaceutical manufacturing facility. The company aims to decide on the location by the end of this year. The site could be in St Petersburg, Moscow or the Moscow region.
“It is good to develop existing sites, but there is an objective need to create a new one,” Rodionov said. “We are still deciding exactly where, also depending on various incentives, where we will implement the project.”
The company’s total investment programme for this year is estimated at 2 billion roubles, GxP News reports. In 2025, Geropharm kept production volumes at 2024 levels and expects them to remain stable in 2026. In 2027, it plans a 50% increase driven by new product launches. Meanwhile, the company’s turnover doubled last year due to demand for obesity and type 2 diabetes drugs, with EBITDA growth exceeding 100%.
